Literature DB >> 22262126

Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy.

Hongxia Zhu1, Zaozao Wang, Qing Xu, Ye Zhang, Yirui Zhai, Jinfeng Bai, Mei Liu, Zhouguang Hui, Ningzhi Xu.   

Abstract

Renal cell carcinoma is resistant to chemotherapy and radiotherapy. STAT1 is overexpressed in human RCC tissue. Downregulation of STAT1 expression could significantly increase the radiosensitivity in RCC cell lines. To further investigate the function of STAT1 in RCC resistance to chemoradiotherapy, a stable STAT1 knockdown cell line was established. Knockdown of STAT1 led to significant growth suppression in vitro and in vivo. Inhibition of STAT1 sensitized 786-O cells to radiotherapy and Taxol treatment. Cells with low STAT1 expression accumulated more strongly in the G 2/M phase after treatment with chemotherapy and radiotherapy. The Human Cell Cycle and DNA Damage Signaling Pathway Real-time PCR arrays were performed and 3 genes upregulated and 16 genes downregulated after STAT1 knockdown were selected. Functional gene grouping showed that genes involved in the M phase, S phase and DNA replication did not differ between the two cell lines. G 1 phase related genes ANAPC2, CCNE1, CUL1 were downregulated, and G 2/M checkpoint genes p21, GADD45A and Rb were strongly reduced by STAT1 knockdown. DNA damage-related genes GADD45A, MAP2K6, were significantly downregulated. The results prove that overexpression of STAT1 in human RCC is associated with the chemoradioresistance. Targeting of STAT1 might be a potential strategy to sensitize RCC to chemotherapy and radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22262126     DOI: 10.4161/cbt.19291

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  12 in total

Review 1.  Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.

Authors:  Shankar Siva; Gargi Kothari; Alexander Muacevic; Alexander V Louie; Ben J Slotman; Bin S Teh; Simon S Lo
Journal:  Nat Rev Urol       Date:  2017-06-20       Impact factor: 14.432

2.  Significance of cyclooxygenase-2, prostaglandin E2 and CD133 levels in sunitinib-resistant renal cell carcinoma.

Authors:  Lei Luo; Ye Liang; Xuemei Ding; Xiaocheng Ma; Guiming Zhang; Lijiang Sun
Journal:  Oncol Lett       Date:  2019-06-06       Impact factor: 2.967

3.  Lysosomal acid lipase promotes cholesterol ester metabolism and drives clear cell renal cell carcinoma progression.

Authors:  Jun Wang; Mingyue Tan; Jifu Ge; Ping Zhang; Jie Zhong; Le Tao; Qiong Wang; Xuemei Tong; Jianxin Qiu
Journal:  Cell Prolif       Date:  2018-03-23       Impact factor: 6.831

4.  Inhibition of STAT1 sensitizes radioresistant nasopharyngeal carcinoma cell line CNE-2R to radiotherapy.

Authors:  Song Qu; Ya Guo; Shi-Ting Huang; Xiao-Dong Zhu
Journal:  Oncotarget       Date:  2017-07-29

5.  VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance.

Authors:  Weiling Liu; Chuanwang Miao; Shaosen Zhang; Yachen Liu; Xiangjie Niu; Yiyi Xi; Wenjia Guo; Jiahui Chu; Ai Lin; Hongjin Liu; Xinyu Yang; Xinjie Chen; Ce Zhong; Yuling Ma; Yuqian Wang; Shihao Zhu; Shuning Liu; Wen Tan; Dongxin Lin; Chen Wu
Journal:  Signal Transduct Target Ther       Date:  2021-08-30

6.  MicroRNA-613 Enhances Nasopharyngeal Carcinoma Cell Radiosensitivity via the DNA Methyltransferase 3B/Tissue Inhibitor of Matrix Metalloproteinase-3/Signal Transducer and Activator of Transcription-1/Forkhead Box O-1 Axis.

Authors:  Liqiang Deng; Qing Yin; Shuyun Liu; Debao Luo
Journal:  Dis Markers       Date:  2022-08-26       Impact factor: 3.464

Review 7.  Revisiting Telomere Shortening in Cancer.

Authors:  Keiji Okamoto; Hiroyuki Seimiya
Journal:  Cells       Date:  2019-01-31       Impact factor: 6.600

8.  BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.

Authors:  Pei Wan; Zhilin Chen; Weifeng Zhong; Huiming Jiang; Zhicheng Huang; Dong Peng; Qiang He; Nanhui Chen
Journal:  Oncol Rep       Date:  2020-10-08       Impact factor: 3.906

9.  IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment.

Authors:  Ana Maia; Zuguang Gu; André Koch; Mireia Berdiel-Acer; Rainer Will; Matthias Schlesner; Stefan Wiemann
Journal:  Mol Oncol       Date:  2021-02-11       Impact factor: 6.603

10.  RHBDD1 promotes proliferation, migration, invasion and EMT in renal cell carcinoma via the EGFR/AKT signaling pathway.

Authors:  Mingyang Li; Licheng Cai; Xingyuan Wang; Yipeng Yu; Wengang Jian; Guochang Bao; Zhiming Gao; Junsheng Guo; Jian Zhang; Chunsheng Li; Cheng Zhang
Journal:  Mol Med Rep       Date:  2021-09-28       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.